se of galectin-3 as a blood marker for patients with Chagas disease.

Not Applicable

• Conditions: Chronic Chagas Disease with cardiac involvement; B57.2

• Registration Number: RBR-5m6748
• Lead Sponsor: Hospital São Rafael

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-04-14
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Recruitment completed
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

Chagas disease confirmed by 2 different serological tests; optimized drug therapy; NYHA functional class II-III-IV or patients with the indeterminate form; patients of any gender and aged 18 to 70 years.

Exclusion Criteria

Valvulopathy with hemodynamic consequences; chronic use of immunosuppressive agents; renal failure on current treatment by dialysis; acute infections or systemic infections in accordance with the definition of sepsis ACCP/SCCM (American College of Chest Phisicians/Society of Critical Care Medicine); abuse alcohol or illicit drugs (Based on DSM IV), any comorbidity with impact on survival in two years; liver, pulmonary, hematologic, neoplastic, bone, inflammatory or infectious diseases.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Expected outcome: Higher serum levels of galectin-3 in the most severe forms of presentation of Chagas disease; detected by ELISA; observing an increase of about 5 ng/mL in patients with the most severe forms when compared with patients with the indeterminate form.

Secondary Outcome Measures

Name	Time	Method
Expected outcome: Higher serum levels of galectin-3 in the patients with myocardium fibrosis; detected by ELISA; observing an increase of about 5 ng/mL in patients with myocardium fibrosis when compared with patients without fibrosis.